Category: Research Publications

Adolescents with eating disorders presenting for treatment were categorized by their binge/purge symptoms and compared on clinical presentation.

Adolescents with eating disorders presenting for treatment were categorized by their binge/purge symptoms and compared on clinical presentation. The three presentation categories compared were: (1) regular objective binge eating and purging (2) regular subjective binge eating and purging and (3) purging without any binge eating. Adolescents who engaged in any...

In this paper we identified the involvement of a thalamic nucleus in the brain responsible for the expression of stress-related memory.

This review examined existing data and found that cognitive-behavior therapy for perfectionism (CBT-P) is effective in reducing risk for anxiety, depression, and eating disorders.

This paper describes the development and deployment of 1) a regional forum of regulatory professionals (ReGARDD) from Clinical and Translational Science Award (CTSA)-funded institutions designed to build and capitalize on local expertise and 2) a regulatory guidance website (ReGARDD.org) geared toward academic researchers that reached 6000+ users in 2019 and...

In our daily life, even in the face of multiple sound sources, our brain binds together frequency components that belong to the same source and recognizes individual sound objects, such as our conversations. We found that a higher-order auditory cortex, the A2 area, plays a critical role in this sound...

Through the lens of the experiences of and challenges for Clinical and Translation Science Award (CTSA) institutions, this paper addresses how COVID-19 has impacted informed consent for clinical research, including an overview of informed consent and the challenges that existed prior to COVID-19, modifications to informed consent processes in response...

Individuals face discrimination and discriminatory experiences (DE) based on characteristics including race/ethnicity, gender, age, and disability. This report assessed whether lifetime DE are associated with changes in brain structure (e.g. cortical thinning) and clinical outcomes across time. This report provides the first evidence to date of an association between DE...

Brexanolone (Zulresso) is the first Federal Drug Administration (FDA) approved drug for the treatment of postpartum depression (PPD). Brexanolone is a positive allosteric modulator of the GABAA receptor, and is given over 60 hours by infusion in a medical setting. This drug has been shown to be effective at significantly reducing...